Evaluation of the Detection of Atrial Fibrillation by a Wearable Dynamic ECG Recorder

NCT ID: NCT04462653

Last Updated: 2020-07-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-24

Study Completion Date

2020-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Randomized, Crossover Trial is conducted to Evaluate Consistency Atrial fibrillation diagnosis between the Wearable Dynamic ECG Recorder and the Control device.

In this investigation, the following indicators is also evaluated:

1. Sensitivity and specificity of the ECG App algorithm in detecting atrial fibrillation compared with physician-adjudicated Gold Standard ECG recorder.
2. Waveform qualitative assessment
3. Safety incident assessments. 114 subjects (60 healthy subjects in phase I and 54 subjects with atrial fibrillation diagnosis in phase II) are enrolled in the investigation according to the criteria.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

use two kinds of device successively

the same participant use a Wearable Dynamic ECG Recorder and 12-lead ECG to record heart rate and atrial fibrillation

Group Type EXPERIMENTAL

Wearable Dynamic ECG Recorder

Intervention Type DEVICE

use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation

12-lead ECG recordings

Intervention Type DEVICE

use a 12-lead ECG recordings to record heart rate and atrial fibrillation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wearable Dynamic ECG Recorder

use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation

Intervention Type DEVICE

12-lead ECG recordings

use a 12-lead ECG recordings to record heart rate and atrial fibrillation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- All study participants must be able to provide written informed consent prior to study procedure. This study has 2 Phases.

Phase 1:

* Health conscious individuals
* \> 18 years of age

Phase 2:

* \> 18 years of age
* non critical patients ever diagnosed with atrial fibrillation

Exclusion Criteria

* • \< 18 years old

* Unable to consent

Phase 1:

* \> 80 years of age
* Previous history of cardiac disease (e.g., atrial fibrillation, myocardial infarction, congestive heart failure)
* current status of non-sinus heart rhythm

Phase 2:

\- Critical patients
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Huami Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ruogu.li

Chief Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shanghai Chest hospital

Shanghai, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ruogu li, MD

Role: CONTACT

86-013916139778

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ruogu Li, MD

Role: primary

86-013916139778

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BZYL-5-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Diagnosis of HCM With AI-ECG
NCT06287892 RECRUITING